Allergic bronchopulmonary aspergillosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Jan 2026NOXAFIL: New indication approved
FDAcompleted
Jan 2026NOXAFIL: New indication approved
FDAcompleted
Jan 2026NOXAFIL: New indication approved
FDAcompleted
Jan 2026NOXAFIL: New indication approved
FDAcompleted
Jan 2026A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA

Qianfoshan Hospital

TrialRECRUITING
Dec 2025A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA

Qianfoshan Hospital

TrialNOT YET RECRUITING
Aug 2025Immune Status and Disease Control of Inflammatory Airway Diseases

First Affiliated Hospital of Ningbo University

TrialRECRUITING
Jul 2025Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis

First Affiliated Hospital of Ningbo University

TrialRECRUITING
May 2025Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis

Qianfoshan Hospital

TrialRECRUITING
May 2025iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

Radboud University Medical Center — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Allergic bronchopulmonary aspergillosis.
Check the disease page for updates →

Approved Treatments

3 FDA-approved

Noxafil

(posaconazole)Orphan drug

Merck Sharp & Dohme LLC

Azole Antifungal [EPC]

12.1 Mechanism of Action Posaconazole is an azole antifungal agent [see Clinical Pharmacology (12.4) ] .

Approved Jan 2026FDA label ↗

Cresemba

(isavuconazonium sulfate)Orphan drug

Astellas Pharma Global Development Inc.

12.1 Mechanism of Action Isavuconazonium sulfate is the prodrug of isavuconazole, an azole antifungal [see Microbiology ( 12.4 )] .

Approved Dec 2023FDA label ↗

Dupixent

(dupilumab)Orphan drugstandard

Regeneron Pharmaceuticals, Inc.

Interleukin-4 Receptor alpha Antagonist [EPC]

12.1 Mechanism of Action Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by spec...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

7 active trials
1Phase 3
1Phase 2
4Unknown
1PHASE2, PHASE3
7Total recruiting
Search clinical trials for Allergic bronchopulmonary aspergillosis

Recent News & Research

No recent news articles indexed yet for Allergic bronchopulmonary aspergillosis.
Search PubMed for Allergic bronchopulmonary aspergillosis

Browse all Allergic bronchopulmonary aspergillosis news →

Specialist Network

Top 6 by expertise

View all Allergic bronchopulmonary aspergillosis specialists →

Quick Actions